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Abstract
Objective The aim was to examine whether inflammatory US features in erosive hand OA patients
change when discontinuing intake of NSAIDs before US examination in a non-randomized study.
Methods Patients (n¼ 99) were allocated to the NSAIDs or control group according to their intake at baseline.
US was performed at baseline (T0) and 2 weeks after discontinuation of NSAIDs (T1). Inflammatory features (i.e.
synovial proliferation, effusion and power Doppler signal) were scored using a semi-quantitative scale (from
zero to three). Pain levels were scored on a numerical rating scale. Binomial mixed models were fitted for US
features, and odds ratios of having a US score of at least two vs at most one for synovial proliferation and effu-
sion, and zero vs at least one for power Doppler were calculated.
Results At baseline, both groups [NSAIDs group (n¼ 47) vs control group (n¼ 52)] were comparable
for numerical rating scale pain, disease duration, number of radiographically affected joints, BMI and
US baseline data, but not for age (P¼ 0.005). At T1, more synovial proliferation and power Doppler sig-
nal was seen compared with T0 in the NSAIDs group (P¼ 0.018 and 0.031, respectively). However, the
interaction term time*NSAIDs was not found to be significant for any variable. The numerical rating
scale pain at T1 was higher compared with baseline, although statistically non-significant.
Conclusion No significant changes in inflammatory US features were seen in patients with erosive
hand OA after withdrawal of NSAIDs for 2 weeks. This study suggests that an NSAID-free period is
not necessary before assessing inflammatory disease activity in erosive hand OA.
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Introduction
Hand OA is a common musculoskeletal disorder mainly
affecting post-menopausal women [1, 2]. A specific sub-
type, the erosive type of hand OA, is known for its
severe inflammatory burden [3, 4] and substantial dis-
ability [5]. Currently, the pharmacological treatment of
hand OA is restricted to symptomatic treatment [6]. For
this purpose, NSAIDs are widely used agents in hand
OA. Although useful for offering symptomatic relief and
reducing inflammation, they do not prevent joint de-
struction or alter the course of the disease.
US is a useful and widely used imaging modality to
assess inflammatory features in patients with hand OA
[7–9]. Few studies have addressed the effect of NSAIDs
on inflammatory US features. One study in knee OA
Key messages
. Cessation of NSAIDs does increase the inflammatory sonographic features in erosive hand OA in the short term.
. However, the interaction term time*NSAIDs was not found to be significant for any variable.
. Interruption of NSAIDs before sonographic assessment of inflammatory activity in erosive hand OA is
not necessary.
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showed a reduction of inflammatory US features, i.e. ef-
fusion and synovial proliferation, after treatment with cel-
ecoxib for 8 weeks [10]. In RA, it was demonstrated that
intake of NSAIDs suppresses grey-scale and power
Doppler signs despite ongoing disease activity [11].
Hence, these US findings seem to underestimate the
patient’s current disease state.
To date, it is unknown whether cessation or interrup-
tion of intake of NSAIDs is mandatory before assessing
inflammatory disease activity in erosive hand OA.
The aim of the study was to examine whether intake
of NSAIDs affects the inflammatory US features in ero-
sive hand OA.
Methods
Patients and study design
Ninety-nine consecutive patients with erosive hand OA
were enrolled in this prospective, non-randomized inter-
vention trial. Patients with erosive hand OA, presenting
to the outpatient clinic of the Rheumatology department
of the Ghent University Hospital, were included.
All patients met the ACR criteria for hand OA [12] and
were 45 years of age. Central radiographic erosions
had to be present in at least two finger IP joints.
Exclusion criteria were as follows: trauma or surgery
performed to the hands within 6 months before baseline,
any IA injection of finger IP joints within 3 months before
inclusion, intake of oral CSs 1 month before inclusion,
positive RF and/or ACPA titres, carpal tunnel syndrome
or any other inflammatory joint disease, such as RA,
PsA or crystal arthropathy. The study was approved by
the local ethics committee, and all procedures followed
were in accordance with the Declaration of Helsinki. All
patients gave oral and written informed consent.
Intervention and sonographic assessments
Regular intake of NSAIDs was registered. If patients
reported taking on a regular base (i.e. 3 days a week)
any NSAIDs at a therapeutic anti-inflammatory dose
[13], they were allocated to the intervention (NSAID with-
drawal) group. In the event of no regular intake of
NSAIDs, the patient was allocated to the control (no
NSAIDs) group. At baseline (T0), US examination of all
16 finger IP joints (i.e. PIP joints 2–5 and DIP joints 2–5
bilaterally) was performed. Patients taking NSAIDs at
baseline were requested to discontinue any intake of
NSAIDs for 2 weeks, after which another US was per-
formed (T1). Patients in the control group also under-
went US after 2 weeks, with the strict request not to
take any NSAIDs in the meantime. Intake of paracetamol
was not allowed in either group.
All US examinations were performed by the same so-
nographer (R.W.), who had >10 years of experience in
musculoskeletal US [9], using an Esaote MyLab60 ma-
chine (Esaote, Genova, Italy) with a 12–18 MHz linear ar-
ray transducer. Settings were optimized to obtain the
best image. The sonographer was blinded to the clinical
findings and allocation of the patient. All examinations
were performed in the same conditions and at the same
time of the day. The presence of synovial proliferation,
effusion and power Doppler was recorded from the dor-
sal and palmar side. Synovial proliferation and effusion
were scored according to the OMERACT atlas for hand
OA from zero to three (zero: absent; one: minimal; two:
mild; three: severe) [14]. Power Doppler settings were
standardized with a pulse repetition frequency of
13.2 kHz and medium wall filter. Settings were adapted
individually to reduce background noise.
Other assessments
At T0, demographic characteristics (age, disease duration
and sex) were recorded. Patients were asked to indicate
the level of pain experienced in the hands during the past
48 h on a numerical rating scale from 0 to 10 (0: no pain;
10: worst pain). Conventional radiographs of the hands
were taken and scored for the presence of erosive fea-
tures according to the anatomical phase scoring system
[15]. Joints were categorized into non-erosive (including
N, S and J phase) vs erosive phases (E, R, F).
Statistical analysis
Baseline demographics, radiographic features and US
features were calculated (mean and S.D. for continuous
variables, and median and range for categorical varia-
bles) and groups were compared using Student’s un-
paired t-test and the Mann–Whitney U-test according to
data distribution. Proportional statistics were assessed
using the v2 test and Fisher’s exact test.
Given that patients were not allocated randomly to ei-
ther the control group (no NSAIDs) or the intervention
group (NSAID withdrawal), models were adjusted for po-
tential confounders of the association between group
and US score. It was decided not to approach the US
scores as nominal variables but to dichotomize (zero or
one vs two or three) for synovial proliferation and effu-
sion, because of a low prevalence of score three and
potential over-interpretation of score one. For the power
Doppler signal, zero vs greater than one was chosen,
because of a low prevalence of power Doppler scores
of two and three. Although anatomical phase was not
considered as a confounder in exploratory analyses, po-
tential phases were dichotomized, resulting in a more
parsimonious model.
Binomial mixed models with a logit function were fit-
ted for US scores of synovial proliferation (score greater
than two), effusion (score greater than two) and power
Doppler (score greater than one), with a random inter-
cept for patient and with age (in years), sex (female vs
male), duration of illness (in years), joint (PIP2 vs PIP3 vs
PIP4 vs PIP5 vs DIP2 vs DIP3 vs DIP4 vs DIP5), side
(left vs right), anatomical phase group (non-erosive vs
erosive phases), NSAID group (NSAID withdrawal vs no
NSAIDs), time (T1 vs T0) and a two-way interaction be-
tween NSAID group time as fixed factors. The regres-
sion coefficients from these models are subject-specific
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parameters and should be interpreted given the subject-
specific values of the random effects. The odds ratio
(OR, 95% CI) of having an US score of at least two vs
having an US score of at most one for synovial prolifera-
tion and effusion, and of having a US score of at least
one vs zero for power Doppler is given.
Analyses were performed using IBM SPSS software
v.25.0 (Armonk, NY, USA).
Results
Demographics
The NSAID withdrawal group consisted of 47 patients
(77% female) and the no NSAIDs group of 52 patients
(79% female). Except for age (P¼0.005), both groups
were comparable for disease duration, numerical rating
scale pain, BMI and number of radiographic affected
joints (Table 1).
Baseline sonographic features
At baseline, for a given age, sex, duration of illness,
joint, side and anatomical phase group, all inflammatory
US features (i.e. synovial proliferation, effusion, and
power Doppler) were comparable between the no
NSAIDs and NSAID withdrawal group (Table 1).
Effect of time and NSAID withdrawal
Pain
At T1, the mean change in numerical rating scale pain
compared with baseline increased more in the NSAID
withdrawal group than in the no NSAID group, albeit sta-
tistically non-significant [0.53 (S.D. ¼ 2.06) vs 0.29 (S.D. ¼
1.80), respectively, P¼ 0.53].
Synovial proliferation
Within the no NSAID group, for a given age, sex, dura-
tion of illness, joint, side and anatomical phase group,
the odds for having a US score of at least two at T1
was 1.30 times the odds at baseline (¼ 30% higher
odds at T1 compared with baseline; OR ¼ 1.304; 95%
CI, 0.958, 1.775; P¼0.091). Within the NSAID with-
drawal group, for a given age, sex, duration of illness,
joint, side and anatomical phase group, the odds of hav-
ing a US score of at least two at T1 was significantly
TABLE 1 Demographic and radiographic data (patient level) and T0 and T1 sonographic data (joint level)
NSAID withdrawal
(n 5 47 patients)
No NSAIDs
(n 5 52 patients)
P-value*
Demographic data
Female, n (%) 36 (77) 41 (79) 0.788
Age, mean (S.D.), years 59 (6.3) 63 (8.5) 0.005
Disease duration, mean
(S.D.), years
11 (6.8) 14 (8.3) 0.066
NRS pain, mean (S.D.) 4.7 (2.3) 3.9 (2.4) 0.139




5 (4–8) 6 (4–7) 0.228
Sonographic scores
NSAID withdrawal
(n 5 751 joints)b
No NSAIDs
(n 5 822 joints)c
OR (95% CI)
(P-value)
Synovial proliferation, n (%) T0 T1 T0 T1
Grade 0 445 (59) 393 (52) 443 (54) 390 (48) 0.584 (0.328, 0.038) (0.067)
Grade 1 239 (32) 265 (35) 268 (32) 298 (36)
Grade 2 61 (8) 90 (12) 89 (11) 124 (15)
Grade 3 6 (<1) 3 (<1) 22 (3) 10 (1)
Effusion, n (%)
Grade 0 335 (45) 297 (40) 396 (48) 391 (48) 1.364 (0.811, 2.293) (0.242)
Grade 1 282 (38) 306 (41) 315 (38) 317 (38)
Grade 2 124 (17) 129 (17) 105 (13) 101 (12)
Grade 3 10 (1) 19 (2) 6 (1) 13 (2)
Power Doppler signal, n (%)
Grade 0 683 (91) 659 (88) 747 (92) 745 (91) 0.846 (0.508, 1.409) (0.520)
Grade 1 49 (7) 64 (8) 55 (7) 45 (5)
Grade 2 17(2) 27 (3) 18 (2) 29 (4)
Grade 3 2 (<1) 1 (<1) 2 (<1) 3 (<1)
aDefined by anatomical phase score, including E, R and F. bOne joint missing owing to amputation. cTen joints missing
from three patients [one joint from two patients owing to amputation; total left hand (eight joints) missing in one patient
owing to amputation]. *P-value reflects comparison between NSAID withdrawal vs no NSAIDs. NRS: numerical rating scale;
OR: odds ratio.
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higher compared with baseline (OR ¼ 1.552; 95% CI,
1.079, 2.232; P¼ 0.018; Table 2).
Effusion
At T1, within the no NSAID group, for a given age, sex,
duration of illness, joint, side and anatomical phase
group, the odds of having a US score of at least two
was 1.02 times the odds at baseline (OR ¼ 1.027; 95%
CI, 0.761, 1.387; P¼0.860). Within the NSAID with-
drawal group, for a given age, sex, duration of illness,
joint, side and anatomical phase group, the odds for
having a US score of at least two at T1 were not signifi-
cantly different compared with baseline (OR ¼ 1.164;
95% CI, 0.872, 1.554; P¼0.303; Table 2).
Power Doppler signal
At T1, within the no NSAIDs group, for a given age, sex,
duration of illness, joint, side and anatomical phase
group, the odds for having a US score of greater than
one was 1.01 times the odds at baseline (OR ¼ 1.016;
95% CI, 0.715, 1.444; P¼0.929). Within the NSAID with-
drawal group, for a given age, sex, duration of illness,
joint, side and anatomical phase group, the odds of hav-
ing a US score of greater than one at T1 was signifi-
cantly higher compared with baseline (OR ¼ 1.480; 95%
CI, 1.036, 2.116; P¼ 0.03; Table 2).
Interaction term NSAIDs*time
The interaction term NSAIDs*time was not found to be
statistically significant for synovial proliferation, effusion
or power Doppler, implying that there was no indication
that the change in odds between T0 and T1 was differ-
ent for the no NSAID group and the NSAID withdrawal
group (P¼ 0.47, 0.56 and 0.14, respectively; Table 2).
Discussion
To our knowledge, these results are the first to suggest
that withdrawal of NSAID intake does not affect the
presence of inflammatory sonographic findings in ero-
sive hand OA. This accounts for synovial proliferation,
joint effusion and the power Doppler signal. These
results are in line with previous results in hand OA
showing that parenteral CSs could not suppress syno-
vial hypertrophy or the power Doppler signal, although a
significant reduction of pain was seen [16]. Our results
contrast with knee OA results, where celecoxib was
able to suppress US inflammation after 8 weeks [10].
Pharmacological therapy in hand OA has hitherto been
limited to symptomatic treatment, such as paracetamol
and NSAIDs [6]. In clinical trials, NSAIDs are often dis-
continued temporarily or permanently in order not to in-
fluence the assessment of disease activity, either
clinically or by US. Our results suggest that there is no
need to interrupt treatment and expose our patients un-
necessarily to more symptoms of pain and/or
inflammation.
The effect of NSAIDs on structural lesions was not
studied here, because the interval between the two US
assessments was too short.
Few studies have reported on the sensitivity to
change of US in hand OA, and they were not able to
demonstrate changes [6, 16], in contrast to rheumatic
disorders such as RA and gout, where US was found to
be responsive [17–20]. Therefore, it remains unknown
whether US is, in fact, capable of detecting inflamma-
tory changes in hand OA.
Although this was not a randomized trial, baseline
data, clinical and US features were comparable between
both groups. It could be hypothesized that patients reg-
ularly taking NSAIDs experience higher level of pain and
inflammation, but this was not the case. The type of
NSAID intake was heterogeneous, but patients were al-
located to the NSAID group when a regular intake of a
standard anti-inflammatory dose was reported (i.e.
3 days per week), and it can be assumed that the
anti-inflammatory effect of NSAIDs is comparable
among several compounds [13].
The study has several limitations. Only one sonogra-
pher performed all the US examinations; however, this
sonographer has >10 years of experience in US and has
proven good inter- and intra-reader reliability in previous
research [9]. Also,
TABLE 2 Change in US scores: unadjusted (crude) and adjusted analyses
Variable Group Crude OR 95% CI P-value Adjusted
ORa
95% CI P-value
Synovial proliferation No NSAIDs 1.263 0.949, 1.681 0.109 1.304 0.958, 1.775 0.091
NSAID withdrawal 1.475 1.048, 2.075 0.026 1.552 1.079, 2.232 0.018
Interaction term time*NSAIDs – – 0.496 – – 0.470
Effusion No NSAIDs 1.022 0.764, 1.367 0.883 1.027 0.761, 1.387 0.860
NSAID withdrawal 1.150 0.872, 1.517 0.324 1.164 0.872, 1.554 0.303
Interaction term time*NSAIDs – – 0.566 – – 0.562
Power Doppler signal No NSAIDs 1.226 0.777, 1.936 0.381 1.016 0.715, 1.444 0.929
NSAID withdrawal 1.194 0.739, 1.928 0.469 1.480 1.036, 2.116 0.031
Interaction term time*NSAIDs 0.936 – – 0.14
aOR in generalized linear model with adjustment for age, BMI, disease duration and anatomical phase. OR: odds ratio.
Statistically significant changes in bold.
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the intake of NSAIDs was monitored by the patients,
but no external control was available. Although explicitly
insisted, it could be possible that unauthorized intake of
NSAIDs happened during the interval period of
withdrawal.
Ideally, a randomized prospective study with standard
NSAID intake, one dose regimen, controlled washout
and greater sample sizes is needed to confirm the ab-
sence of causality between NSAIDs and US inflamma-
tion in erosive hand OA.
In conclusion, our study suggests that NSAIDs do not
influence the sonographic features of inflammation in
patients with hand OA; hence, discontinuation is not
necessary before US assessment.
Acknowledgements
We thank Miss Anuschka Van den Bogaert for the logis-
tic and administrative support and Dr Stefanie De
Buyser for the statistical support.
Funding: No specific funding was received from any
funding bodies in the public, commercial or not-for-
profit sectors to carry out the work described in this
manuscript.
Disclosure statement: The authors have declared no
conflicts of interest.
References
1 Dahaghin S, Bierma-Zeinstra SMA, Ginai AZ et al.
Prevalence and pattern of radiographic hand
osteoarthritis and association with pain and disability
(the Rotterdam study). Ann Rheum Dis 2005;64:682–7.
2 Haugen IK, Englund M, Aliabadi P et al. Prevalence,
incidence and progression of hand osteoarthritis in the
general population: the Framingham Osteoarthritis Study.
Ann Rheum Dis 2011;70:1581–6.
3 Haugen IK, Mathiessen A, Slatkowsky-Christensen B
et al. Synovitis and radiographic progression in non-
erosive and erosive hand osteoarthritis: is erosive hand
osteoarthritis a separate inflammatory phenotype?
Osteoarthritis Cartilage 2016;24:647–54.
4 Bijsterbosch J, Watt I, Meulenbelt I et al. Clinical burden
of erosive hand osteoarthritis and its relationship to
nodes. Ann Rheum Dis 2010;69:1784–8.
5 Zhang Y, Niu J, Kelly-Hayes M et al. Prevalence of
symptomatic hand osteoarthritis and its impact on
functional status among the elderly: The Framingham
Study. Am J Epidemiol 2002;156:1021–7.
6 Kloppenburg M, Kroon FP, Blanco FJ et al. 2018 update
of the EULAR recommendations for the management of
hand osteoarthritis. Ann Rheum Dis 2019;78:16–24.
7 Kortekaas MC, Kwok WY, Reijnierse M, Huizinga TW,
Kloppenburg M. In erosive hand osteoarthritis more
inflammatory signs on ultrasound are found than in the
rest of hand osteoarthritis. Ann Rheum Dis 2013;72:
930–4.
8 Uson J, Fernandez-Espartero C, Villaverde V et al.
Symptomatic and asymptomatic interphalageal
osteoarthritis: An ultrasonographic study. Reumatol Clin
2014;10:278–82.
9 Wittoek R, Carron P, Verbruggen G. Structural and
inflammatory sonographic findings in erosive and non-
erosive osteoarthritis of the interphalangeal finger joints.
Ann Rheum Dis 2010;69:2173–6.
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